Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute

Yu,Wen-Xi; Tang,Li-Na; Lin,Feng; Yao,Yang; Shen,Zan

doi:10.3892/ol.2014.2472

Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute

Authors:
- Wen-Xi Yu
- Li-Na Tang
- Feng Lin
- Yang Yao
- Zan Shen
View Affiliations

Affiliations: Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 200233, P.R. China
Published online on: August 21, 2014 https://doi.org/10.3892/ol.2014.2472
Pages: 2243-2248

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis for patients with relapsed/metastatic osteosarcoma is poor and the optimal treatment strategy remains to be refined. Whilst gemcitabine plus docetaxel combination treatment has already been demonstrated to have certain promising results in the treatment of osteosarcoma, the use of pemetrexed, a multi‑targeted antifolate, remains controversial. In the present study, a retrospective investigation was conducted to evaluate the toxicity and efficacy of the pemetrexed plus cisplatin combination in relapsed/metastatic osteosarcoma. Comparison of this treatment with that of the gemcitabine plus docetaxel combination was also conducted. Clinical data from 39 patients suffering from refractory/metastatic osteosarcoma between January 2005 and May 2011 were reviewed retrospectively. Of these patients, 21 were administered the gemcitabine plus docetaxel combination, and 18 were provided the pemetrexed plus cisplatin combination. Treatment was continued until the occurrence of disease progression or unacceptable toxicity. In the gemcitabine plus docetaxel group, the overall response rate and disease control rate were found to be 9.5 and 28.5% respectively, compared with 5.5 and 33.3% respectively in the pemetrexed plus cisplatin group. The median progression‑free survival (PFS) time was found to be 1.8 months for both the gemcitabine plus docetaxel and pemetrexed plus cisplatin groups. The median overall survival (OS) time was 6 months in the gemcitabine plus docetaxel group and 7 months in the pemetrexed plus cisplatin group. No statistically significant differences were recognized between the overall response rates, disease control rates, PFS times and OS times in the two groups. The two combinations appeared to be well tolerated. However, the incidence of grade 3/4 thrombocytopenia and leucopenia was higher in the gemcitabine plus docetaxel group than in the pemetrexed plus cisplatin group. The present study clearly demonstrated that both chemo‑combinations were well‑tolerated and exerted antitumor activity in patients with refractory/metastatic osteosarcoma. However, with regard to grade 3/4 toxicity, the pemetrexed plus cisplatin chemotherapy appears to be better tolerated.

View Figures

View References

1	Arndt CA and Crist WM: Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 341:342–352. 1999.
2	Friedman MA and Carter SK: The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol. 4:482–510. 1972.
3	Ozaki T, Flege S, Kevric M, et al: Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 21:334–341. 2003.
4	Tabone MD, Kalifa C, Rodary C, et al: Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 12:2614–2620. 1994.
5	Kempf-Bielack B, Bielack SS, Jürgens H, et al: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 23:559–568. 2005.
6	Biccoli A, Rocca M, Salone M, et al: Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer. 104:1721–1725. 2005.
7	Bielack SS, Kempf-Bielack B, Branscheid D, et al: Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 27:557–565. 2009.
8	Briccoli A, Rocca M, Salone M, et al: High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005. Surg Oncol. 19:193–199. 2010.
9	Zhang Y, Xiao JP, Zhang HZ, et al: Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. Chin Med J (Engl). 124:4132–4137. 2011.
10	Hogendoorn PC, Athanasou N and Bielack S; ESMO/EUROBONET Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 5): 204–213. 2010.
11	Qi WX, He AN, Tang LN, Shen Z and Yao Y: Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol. 29:2229–2233. 2012.
12	Seibel NL, Krailo M, Chen Z, et al: Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children’s Cancer Group (CCG) 7943. Cancer. 109:1646–1653. 2007.
13	Crews KR, Stewart CF, Liu T, Rodriguez Galindo C, Santana VM and Daw NC: Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J Pediatr Hematol Oncol. 26:764–767. 2004.
14	Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, et al: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children’s Oncology Group study. Pediatr Blood Cancer. 50:254–258. 2008.
15	De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, et al: Temozolamide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer. 47:30–36. 2006.
16	Carmichael J: The role of gemcitabine in the treatment of other tumours. Br J Cancer. 78(Suppl 3): 21–25. 1998.
17	Trudeau ME: Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol. 6:443–457. 1996.
18	Merimsky O, Meller I, Kollender Y and Inbar M: Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer. 34:1296–1297. 1998.
19	Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S and Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer. 94:3225–3229. 2002.
20	Leu KM, Ostruszka LJ, Shewach D, et al: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 22:1706–1712. 2004.
21	Navid F, Willert JR, McCarville MB, et al: Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 113:419–425. 2008.
22	Mora J, Cruz CO, Parareda A and de Torres C: Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 31:723–729. 2009.
23	Geoerger B, Chisholm J, Le Deley MC, et al: European Consortium Innovative Therapies for Children with Cancer: Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. Eur J Cancer. 47:230–238. 2011.
24	Qi WX, He AN, Tang LN, et al: Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol. 42:427–431. 2012.
25	He A, Qi W, Huang Y, et al: Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. Int J Clin Oncol. 18:498–505. 2013.
26	Shih C, Habeck LL, Mendelsohn LG, et al: Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul. 38:135–152. 1998.
27	Hartmann JT, Bauer S, Egerer G, et al: Pemetrexed in patients with refractory soft tissue sarcoma: a non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005. Invest New Drugs. 31:167–174. 2013.
28	Argiris A, Pennella E, Koustenis A, et al: Pemetrexed in head and neck cancer: a systematic review. Oral Oncol. 49:492–501. 2013.
29	Tomasini P, Greillier L, Khobta N and Barlesi F: The place of pemetrexed in the management of non-small-cell lung cancer patients. Expert Rev Anticancer Ther. 13:257–266. 2013.
30	Boons CC, VAN Tulder MW, Burgers JA, et al: The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer Res. 33:3553–3561. 2013.
31	Walling J: From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs. 24:37–77. 2006.
32	Duffaud F, Egerer G, Ferrari S, et al: A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. Eur J Cancer. 48:564–570. 2012.
33	Urba S, van Herpen CM, Sahoo TP, et al: Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer. 118:4694–4705. 2012.
34	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003.
35	Jänne PA, Wozniak AJ, Belani CP, et al: Pemetrexed expanded access program investigators: Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 1:506–512. 2006.
36	Trotti A, Byhardt R, Stetz J, et al: Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 47:13–47. 2000.
37	Cirillo M, Venturini M, Ciccarelli L, et al: Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol. 20:1929–1935. 2009.
38	Bacci G, Briccoli A, Ferrari S, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer. 37:2030–2039. 2001.
39	Bacci G, Ferrari S, Longhi A, et al: Italian Sarcoma Group/Scandinavian Sarcoma Group: High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 14:198–206. 2002.